Paper
24 March 2023 CAR-T cell toxicity: clinical manifestation, contributive factors, and recommendations
Haozhu Liu, Jiajun Wu
Author Affiliations +
Proceedings Volume 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022); 1261143 (2023) https://doi.org/10.1117/12.2669625
Event: International Conference on Biological Engineering and Medical Science (ICBioMed2022), 2022, Oxford, United Kingdom
Abstract
Chimeric antigen receptor (CAR)-T therapy has exhibited the powerful potential and hyperefficient ability in the field of cancer therapy. In last decade, CAR-T therapy has been regarded as first-line methos in curing the lymphoma in adults and ALL in children. Despite the successful made in treating hematological tumor, issues still exist for utilize of CAR-T therapy to eliminate solid tumors. Besides CAR-T Cells have a variety of toxicity in cancer therapy which become the mainstream concern in cancer therapy. While in recent studies, scientist guided the proper use of the CAR-T therapy and devote them self to remold CAR trying to overcome those problems. In this article, CAR-T cell toxicity clinical manifestation, contributive factors to the CAR-T cell toxicity, recommendations for CAR-T therapy and guideline for CAR-T therapy are described.
© (2023) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Haozhu Liu and Jiajun Wu "CAR-T cell toxicity: clinical manifestation, contributive factors, and recommendations", Proc. SPIE 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022), 1261143 (24 March 2023); https://doi.org/10.1117/12.2669625
Advertisement
Advertisement
RIGHTS & PERMISSIONS
Get copyright permission  Get copyright permission on Copyright Marketplace
KEYWORDS
Toxicity

Chromium

Cancer

Tumors

Clinical trials

Animal model studies

Blood

Back to Top